15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering Prelude Therapeutics Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $3.00 to $9.00 (about 3.0x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $6.50 sits 67% above the current $3.89. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.17 next quarter toward $-0.86 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Moderate Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to Prelude Therapeutics Inc.
As of Jul, 4 of 4 firms rate PRLD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
PRLD EPS & revenue forecast
EPS · NEXT QUARTER
$-0.17
Range $-0.18 – $-0.16 · 2 analysts · -35% YoY
Next period, 2 analysts expect Prelude Therapeutics Inc to earn $-0.17 a share (range $-0.18 – $-0.16), versus $-0.26 a year earlier. Full-year consensus is $-0.66, growing to $-0.86 the year after.
REVENUE · NEXT QUARTER
$33.3M
Range $0 – $100.0M · 2 analysts · +413% YoY
Revenue is expected to reach $33.3M (range $0 – $100.0M), +412.8% year-over-year. Full-year consensus is $37.9M, rising to $50.0M next year.
Top analysts covering Prelude Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PRLD.
#1
RB
Robert Burns
HC Wainwright & Co. · Rank #195
Buy
$8.00+105.7% to target
Overall win rate
38%
+ Follow
#2
Reni J. Benjamin
JMP Securities · Rank #290
Buy
$6.00+54.2% to target
Overall win rate
33%
+ Follow
#3
Jason Kolbert
D. Boral Capital · Rank #346
Buy
$9.00+131.4% to target
Overall win rate
22%
+ Follow
#4
Reni J. Benjamin
Citizens
Buy
$6.00+54.2% to target
Coverage
—
+ Follow
PRLD stock forecast FAQ
What is PRLD's average 12-month price target?+
The 4 analysts with a live target average $6.50 for Prelude Therapeutics Inc over the next 12 months, ranging from a $9.00 high to a $3.00 low.
Is PRLD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for PRLD?+
The Street-high target is $9.00 (D. Boral Capital), and the Street-low is $3.00 (JMP Securities). The average of all 4 active targets is $6.50.
How many Wall Street analysts cover PRLD?+
4 analysts have an active rating on Prelude Therapeutics Inc, and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering PRLD?+
Among analysts who currently cover PRLD, Robert Burns of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #195). Their current call is Buy with a $8.00 target.
What is Prelude Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.17 per share (range $-0.18 – $-0.16) across 2 analysts. Full-year EPS is projected at $-0.66, rising to $-0.86 the following year.
How much revenue is Prelude Therapeutics Inc expected to report next quarter?+
Consensus revenue is $33.3M (range $0 – $100.0M). Full-year revenue is projected at $37.9M, growing to $50.0M next year.
Have analysts been upgrading or downgrading PRLD lately?+
As of Jul, 4 of 4 firms rate PRLD a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PRLD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
